- Home
- AC vs GERN Comparison
AC vs GERN Comparison
Compare AC & GERN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- AC
- GERN
- Stock Information
- Founded
- AC 1976
- GERN 1990
- Country
- AC United States
- GERN United States
- Employees
- AC N/A
- GERN N/A
- Industry
- AC Investment Bankers/Brokers/Service
- GERN Biotechnology: Pharmaceutical Preparations
- Sector
- AC Finance
- GERN Health Care
- Exchange
- AC Nasdaq
- GERN Nasdaq
- Market Cap
- AC 809.6M
- GERN 840.7M
- IPO Year
- AC N/A
- GERN 1996
- Fundamental
- Price
- AC $35.80
- GERN $1.18
- Analyst Decision
- AC
- GERN Buy
- Analyst Count
- AC 0
- GERN 9
- Target Price
- AC N/A
- GERN $5.13
- AVG Volume (30 Days)
- AC 4.8K
- GERN 11.2M
- Earning Date
- AC 05-08-2025
- GERN 05-07-2025
- Dividend Yield
- AC 6.06%
- GERN N/A
- EPS Growth
- AC 16.36
- GERN N/A
- EPS
- AC 1.80
- GERN N/A
- Revenue
- AC $12,293,000.00
- GERN $116,293,000.00
- Revenue This Year
- AC N/A
- GERN $194.54
- Revenue Next Year
- AC N/A
- GERN $56.51
- P/E Ratio
- AC $19.82
- GERN N/A
- Revenue Growth
- AC N/A
- GERN 22264.04
- 52 Week Low
- AC $28.58
- GERN $1.17
- 52 Week High
- AC $43.85
- GERN $5.34
- Technical
- Relative Strength Index (RSI)
- AC 53.33
- GERN 32.46
- Support Level
- AC $34.30
- GERN $1.34
- Resistance Level
- AC $36.90
- GERN $1.44
- Average True Range (ATR)
- AC 1.02
- GERN 0.10
- MACD
- AC 0.13
- GERN 0.00
- Stochastic Oscillator
- AC 68.57
- GERN 3.23
About AC Associated Capital Group Inc.
Associated Capital Group Inc is a diversified global financial services company. It operates in the business of alternative investment management, institutional research services, and cash and other assets through subsidiaries. The activities of its subsidiaries comprise publishing daily research notes and full reports using private market value with a catalyst methodology and also products and customized solutions utilizing private market value with catalyst method of investing.
About GERN Geron Corporation
Geron Corp is a clinical-stage biopharmaceutical company focused on the research and development of cancer treatments. The company's drug in development, Imelstat, is being tested for the treatment of myelodysplastic syndromes, which are disorders of the blood, and myelofibrosis, which is a rare blood cancer affecting bone marrow. The company earns revenue through collaboration agreements, milestones, royalties, and licensing arrangements. Geron possesses various rights to this drug. The company operates as a single segment being, the development of therapeutic products for oncology.